Biotest develops biotechnological drugs (biotherapeutics/biologics) on the basis of genetically-produced recombinant monoclonal antibodies (mAbs). These therapeutics are highly specific and are characterized by a unique mode of action. They are developed particularly in therapeutic areas with great medical need. With its biotherapeutic products, Biotest endeavors to improve the quality of life of patients with diseases that are currently difficult to treat. Biotest currently has three promising mAbs with high market potential in three different phases of
pre-clinical and clinical development.
